These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 8707731)

  • 1. The comparative efficacy and safety of teicoplanin and vancomycin.
    Wood MJ
    J Antimicrob Chemother; 1996 Feb; 37(2):209-22. PubMed ID: 8707731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM; Bryson HM
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teicoplanin versus vancomycin for proven or suspected infection.
    Cavalcanti AB; Goncalves AR; Almeida CS; Bugano DD; Silva E
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007022. PubMed ID: 20556772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of teicoplanin in the treatment of infections.
    de Lalla F; Tramarin A
    Drug Saf; 1995 Nov; 13(5):317-28. PubMed ID: 8785019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
    Svetitsky S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative efficacy and safety of teicoplanin and vancomycin.
    Cobo J; Fortún J
    J Antimicrob Chemother; 1996 Dec; 38(6):1113-4. PubMed ID: 9023665
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative safety of teicoplanin and vancomycin.
    Wilson AP
    Int J Antimicrob Agents; 1998 May; 10(2):143-52. PubMed ID: 9716291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.
    Kato-Hayashi H; Niwa T; Ohata K; Harada S; Matsumoto T; Kitagawa J; Tsurumi H; Suzuki A
    J Clin Pharm Ther; 2019 Dec; 44(6):888-894. PubMed ID: 31373043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety of teicoplanin and vancomycin.
    Wood MJ
    J Chemother; 2000 Nov; 12 Suppl 5():21-5. PubMed ID: 11131960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis.
    Kalil AC; Murthy MH; Hermsen ED; Neto FK; Sun J; Rupp ME
    Crit Care Med; 2010 Sep; 38(9):1802-8. PubMed ID: 20639754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin.
    Shea KW; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):833-44. PubMed ID: 7791426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
    Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
    J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.